Last updated: April 29, 2026
What is Relistor and how is it positioned commercially?
Relistor is methylnaltrexone bromide, an oral opioid receptor antagonist (peripheral selective) used to treat opioid-induced constipation (OIC). Commercially, it is positioned as an opioid peripheral antagonist option for adults with OIC who may not respond adequately to laxatives.
Key marketed indications (label basis):
- OIC in adults (including those on chronic opioid therapy for non-cancer pain; and in specific geographies/label variations, also other OIC contexts).
- Use after laxatives where applicable by label.
Global commercial context (high-level):
- OIC remains a mature specialty category with competition from other peripherally acting opioid antagonists and newer approaches within constipation care.
- Pricing and share dynamics have shifted over time as newer entrants and broader constipation portfolios expanded formularies and payer scrutiny increased.
What clinical trial activity matters most right now?
Based on publicly available trial records to date, Relistor’s clinical footprint is dominated by:
- Older pivotal trials underpinning current OIC approvals.
- Post-marketing and mechanistic studies tied to safety, dosing, and subpopulations.
- Less frequent late-stage development in new mechanisms because Relistor’s core use case is already established.
Trial landscape that remains relevant
1) OIC efficacy and safety (pivotal era, established endpoints)
- Trials evaluated outcomes such as:
- Time to first bowel movement
- Number of spontaneous bowel movements
- Need for rescue laxatives
- Abdominal pain/discomfort
- Safety monitored for:
- Withdrawal symptoms or loss of opioid analgesia signals
- GI adverse events
2) Subpopulation and real-world alignment
- Studies and analyses typically address:
- Response differences by baseline constipation severity
- OIC risk factors and opioid regimen characteristics
- Tolerability patterns and discontinuation drivers
3) Ongoing and newly registered studies
- As of current publicly accessible registries, there is no dominant, widely reported late-stage program that would materially reset the risk profile or expand indications in a way comparable to a new Phase 3 readout. The clinical question set remains centered on label maintenance, safety monitoring, and niche usage refinements rather than a new wave of broad indication expansion.
Clinical takeaway: the practical “update” for Relistor is that the drug is in a mature phase. The value proposition remains driven by payer coverage and guideline placement within OIC care pathways rather than by imminent Phase 3 data that changes competitive positioning.
How does the competitive set shape Relistor demand?
Relistor competes in the OIC class against other opioid peripheral antagonists and broader constipation strategies. Demand is influenced by:
- Formularies and prior authorization rules
- Step therapy (laxatives first)
- Coverage bias toward agents with favorable evidence summaries for endpoints payers track (rescue use, time-to-response, adherence)
- Patient preference and adherence (route of administration, dosing frequency, onset expectations)
Comparative competitive pressures (category mechanics)
Relistor’s demand is pressured by:
- Class competition within peripherally acting opioid antagonists
- Broader constipation product coverage that payers sometimes treat as substitutes
- Generic or biosimilar adjacency effects in adjacent GI categories that reallocate spend
Relistor retains resilience where:
- Clinicians choose it after inadequate laxative response
- Patients have a history of acceptable efficacy/tolerability
- Formularies keep it within restrictive tiers for OIC
What does the market look like, and where does growth come from?
OIC is a specialty segment inside constipation. Growth drivers typically include:
- Increasing chronic opioid prescribing volume in some markets (offset by opioid stewardship in others)
- Expansion of constipation screening and OIC recognition
- Continued guideline adherence to opioid antagonists when laxatives fail
- Switch dynamics within class due to net price and payer contracting
Counterweights:
- Payer pressure to constrain spend through step edits and formulary narrowing
- Saturation and mature-treatment patterns
- Competition that can shift share by dosing convenience, formulary tiering, or clinical evidence preference
What is the 2025-2035 market projection for Relistor?
A defensible projection requires consistent inputs: net unit growth, price erosion, competitive share shifts, and regional prescribing volumes. Under current constraints, the only accurate projection available from the provided information is directional (not numeric). This response therefore provides projection mechanics and a range framework without stating unsupported absolute market values.
Projection framework (what determines Relistor’s trajectory)
Relistor’s sales in OIC are usually modeled by:
- Eligible patient pool growth
- OIC prevalence and opioid exposure trends
- Penetration within eligible pool
- Share of patients receiving peripheral antagonists after laxatives
- Net price
- Rebates, discounts, payer contracting, and price erosion
- Share drift
- Competitive switching within the class
- Adherence and discontinuation
- Dosing and GI tolerability affect persistence
Scenario structure (base, bear, bull)
Base case drivers
- Modest patient pool growth
- Ongoing price erosion typical of mature specialty brands
- Share stabilization within peripherally acting opioid antagonists
- No major new indication expansion
Bear case drivers
- Accelerated payer restriction and step therapy
- Faster share loss to higher formulary-positioned class competitors
- Higher discontinuation from tolerability or inadequate response
Bull case drivers
- Favorable contracting that improves tier placement
- Evidence-based formulary inclusion in additional health systems
- Better persistence outcomes than peers
Projection directionality
- Relistor is expected to track a mature decline-to-flat path in many markets where price erosion exceeds patient pool growth.
- In markets where payer coverage is stable and OIC diagnosis rates increase, Relistor can sustain low-single-digit growth before settling into plateau.
What events could change Relistor’s trajectory?
Material inflection typically comes from:
- Payer formulary changes tied to contracting cycles
- New head-to-head evidence shifting clinical guidelines within OIC
- Route/dosing improvements in a competitive context (not new Relistor delivery platforms)
- Generic entry or strong price competition in specific territories (brand lifecycle dynamics)
Key takeaways for R&D and investment
- Relistor is a mature OIC therapy with clinical development that is largely label maintenance and safety rather than a new Phase 3 engine.
- Near- to mid-term commercial performance is driven by payer access and competitive positioning inside the peripherally acting opioid antagonist class.
- 2025-2035 outcomes are most likely shaped by pricing and formulary tier dynamics more than by new clinical readouts.
- Forecast confidence is highest when modeled as a patient pool plus penetration-plus-net price problem, with scenario share drift across the class.
Key Takeaways
- Relistor is established in OIC care and is not currently defined by an imminent late-stage clinical expansion.
- The practical market question is access: formulary placement, step therapy, and net pricing.
- The 2025-2035 range most consistent with mature-category behavior is plateau to modest decline, with upside tied to payer contracting and sustained persistence.
FAQs
1) What is Relistor’s primary clinical use?
Relistor (methylnaltrexone bromide) is used for opioid-induced constipation in adults, typically after inadequate response to laxatives, based on label requirements in each geography.
2) Why does Relistor face strong commercial pressure in OIC?
OIC is a competitive specialty segment with multiple peripherally acting opioid antagonists and competing constipation pathways, so formulary access and net price drive share.
3) Is there evidence of major new Phase 3 expansion for Relistor?
The public trial footprint indicates established OIC evidence with limited signal of a new late-stage program that would materially reset indication breadth.
4) What endpoints historically matter most in Relistor trials?
Trials commonly evaluate time to first bowel movement and spontaneous bowel movement frequency, plus rescue-laxative use and symptom tolerability.
5) What is the biggest forecast variable for 2025-2035?
Net pricing and payer access (tier placement, step edits, and contracting cadence) typically outweigh patient pool growth for mature specialty brands like Relistor.
References
[1] U.S. Food and Drug Administration. Drug Approval Reports and Labeling for methylnaltrexone bromide (Relistor).
[2] ClinicalTrials.gov. Methylnaltrexone bromide (Relistor) search results and study records.
[3] EMA. Product information and regulatory assessment documents for methylnaltrexone bromide where available.
